What this study adds:
- To investigate adverse events (AEs) of various hypoglycemic drugs
using data mining procedure based on FDA adverse event reporting
system (FAERS).
- To discuss what makes sodium-glucose co-transporter-2 inhibitors
(SGLT2i) so special, especially for canagliflozin.
- To screen out AEs that might be used as warnings of immanent lower
extremity amputation.